The Management of Essential Thrombocythaemia

References

• Fialkow P. J., Faguet G. B., Jacobson R. J., Vaidya K., Murphy S. (1981) Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent cell. Blood, 58, 916–9.
   PubMed Web of Science ®Google Scholar
• Anger B., Janssen J. W. G., Schrezenmeier H., Hlehlmann R., Heimpel H., Bartram C. R. (1990) Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphism. Leukemia, 4, 258–61.
   PubMed Web of Science ®Google Scholar
• Kassar N. E., Hetet G., Li Y., Briere J., Grandchamp B. (1995) Clonal analysis of haemopoietic cells in essential thrombocythemia. Br. J. Haematol., 90, 131–7.
   PubMed Web of Science ®Google Scholar
• Murphy S., Iland H. J. (1994) Thrombocytosis. In Thrombosis and Hemorrhage (1st ed.) edited by Loscalzo J and Schafer AL, pp. 597–612. Baltimore: Williams and Wilkins Publishers.
   Google Scholar
• Pearson T. C. (1991) Primary Thrombocythaemia: diagnosis and management. Br. J. Haematol., 78, 145–8.
   PubMed Web of Science ®Google Scholar
• Rozman C., Giralt M., Feliu E., Rubio D., Cortés M. T. (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer, 67, 2658–63.
   PubMed Web of Science ®Google Scholar
• Murphy S., Peterson P., Iland H., Laszlo J. (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin. Hematol., 34, 29–39.
   PubMed Web of Science ®Google Scholar
• Murphy S., Iland H. J., Rosenthal D., Laszlo J. (1986) Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin. Hematol., 23, 177–82.
   PubMed Web of Science ®Google Scholar
• Rolovic Z., Basara N., Gotic M., Sefer D., Bogdanovic A. (1995) The determination of spontaneous colony formation is an unequivocal test for discriminating between essential thrombocythemia and reactive thrombocytosis. Br. J. Haematol. 90, 326–31.
   PubMed Web of Science ®Google Scholar
• Sawyer B. M., Westwood N. B., Pearson T. C. (1994) Circulating megakaryocyte progenitor cells in patients with primary thrombocythaemia and reactive thrombocytosis: results using a serum-deprived culture assay and positive detection technique. Eur. J. Haematol., 53, 108–13.
   PubMed Web of Science ®Google Scholar
• Michiels J. J. (1996) The myeloproliferative disorders. An historical appraisal and personal experiences. Leukemia and Lymphoma, 22 (suppl. 1), 1–14.
   PubMed Web of Science ®Google Scholar
• Barbui T., Cortelazzo S., Viero P., Bassan R., Dini E., Semeraro N. (1983) Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and function. Eur. J. Cancer Clin. Oncol., 19, 1593–9.
   PubMedGoogle Scholar
• Bellucci S., Janvier M., Tobelem G. et al. (1986) Essential thrombocythemia: Clinical evolutionary and biological data. Cancer, 58, 2440–7.
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Jahn M., Baumann B., Kopcke W. (1988) Essential thrombocythemia: Clinical characteristics and course of 61 cases. Cancer, 61, 2487–96.
   PubMed Web of Science ®Google Scholar
• Fenaux P., Simon M., Caulier M. T., Lai J. L., Goudemand J., Bauters F. (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer, 66, 549–56.
   PubMed Web of Science ®Google Scholar
• Mitus A. J., Barbui T., Shulman L. N., Rosenthal D. S., Viero P., Cortelazzo S., Schafer A. I. (1990) Hemostatic complications in young patients with essential thrombocythemia. Am. J. Med., 88, 371–5.
   PubMed Web of Science ®Google Scholar
• Colombi M., Radaelli F., Zocchi L., Maiolo A. T. (1991) Thrombotic and hemorrhagic complications in essential thrombocythaemia. Cancer, 67, 2926–30.
   PubMed Web of Science ®Google Scholar
• Budde U., Scharf R. E., Franke P., Hartmann-Budde K., Dent J., Ruggeri Z. M. (1993) Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood, 82, 1749–57.
   PubMed Web of Science ®Google Scholar
• van Genderen P. J. J., Michiels J. J., van der Poel-van de Luytgaarde S. C. P. A. M., van Vliet H. H. D. M. (1994) Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Annals of Hematology, 69, 81–4.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S., Viero P., Finazzi G., D'Emilio A., Rodeghiero F., Barbui T. (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol., 8 556–62.
   PubMed Web of Science ®Google Scholar
• Schafer A. I. (1991) Essential thrombocythemia. Prog. Hemost. Thromb., 10, 69–96.
   PubMedGoogle Scholar
• Tefferi A., Silverstein M. N., Hoagland H. C. (1995) Primary thrombocythemia. Semin. Oncol., 22, 334–40.
   PubMed Web of Science ®Google Scholar
• Barbui T., Finazzi G., Dupuy E., Kiladijan J. J., Brière J. (1996) Treatment strategies in essential thrombocythemia. Leukemia and Lymphoma, 22 (suppl.1), 149–160.
   PubMed Web of Science ®Google Scholar
• Michiels J. J., Koudstaal P. J., Mulder A. H., van Vliet H. H. D. M. (1993) Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology, 43: 1107–10.
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. B.M.J., 308, 81–106.
   PubMed Web of Science ®Google Scholar
• Finazzi G., Budde U., Michiels J. J. (1996) Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Leukemia and Lymphoma, 22 (suppl.1), 71–78.
   PubMed Web of Science ®Google Scholar
• Kelly J. P., Kaufman D. W., Jurgelon J. M., Sheehan J., Koff R. S., Shapiro S. (1996) Risk of aspirin-associated major upper-gastrointestinal bleeding with entericcoated or buffered product. Lancet, 348, 1413–16.
   PubMed Web of Science ®Google Scholar
• Griesshammer M., Heimpel H., Pearson T. C. (1996) Essential thrombocythaemia and pregnancy. Leukemia and Lymphoma, 22, (suppl.1), 57–63.
   PubMed Web of Science ®Google Scholar
• Pagliaro P., Arrigoni L., Muggiasca M. L., Poggio M., Russo U., Russi E. (1996) Primary thrombocyhthemia and pregnancy. Treatment and outcome in fifteen cases. Am. J. Hematol., 53, 6–10.
   PubMed Web of Science ®Google Scholar
• Beressi A. H., Tefferi A., Silverstein M. N., Petitt R. M., Hoagland H. C. (1995) Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch. Intern. Med., 155, 1217–22.
   PubMed Web of Science ®Google Scholar
• Shpilberg O., Shimon I., Sofer O., Dolitski M., Ben-Bassat I. (1996) Transient normal platelet count and decreased requirement for interferon during pregnancy in essential thrombocythemia. Br. J. Haematol., 92, 491–93.
   PubMed Web of Science ®Google Scholar
• Löfvenberg E., Walhlin A. (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur. J. Haematol., 41, 375–381.
   PubMed Web of Science ®Google Scholar
• van Genderen P. J. J., Michiels J. J. (1993) Primary thrombocytemia: diagnosis, clinical manifestations and management. Annals of Hematology, 67, 57–62.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S., Finazzi G., Ruggeri M., et al. (1995) Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N. Engl. J. Med., 332, 1132–6.
   PubMed Web of Science ®Google Scholar
• Murphy S., Peterson P., Iland H. J., Fruchtman S. (1993) Hydroxyurea and other myelosuppressive agents in the treatment of essential thrombocythemia: analysis of leukemogenic potential. Thromb. Haemost., 69, 564 (abst)
   Web of Science ®Google Scholar
• Shibata K., Shimamoto Y., Suga K., Sano M., Matsuzaki M., Yamaguchi M. (1994) Essential Thrombocythemia terminating in acute leukemia with minimal myeloid differentiation. A brief review of recent literature. Acta. Haematol., 91, 84–8.
   PubMed Web of Science ®Google Scholar
• Löfvenberg E., Nordenson I., Walhlin A. (1990) Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet. Cytogenet., 49, 57–67.
   PubMed Web of Science ®Google Scholar
• Nand S., Stock W., Godwin J., Gross Fisher S. (1996) Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am. J. Hematol., 52, 42–46.
   PubMed Web of Science ®Google Scholar
• Weinfield A., Swolin B., Westin J. (1994) Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur. J. Haematol., 52, 134–9
   PubMed Web of Science ®Google Scholar
• Van de Pette J. E. W., Prochazka A. V., Pearson T. C., Singh A. K., Dickson E. R., Wetherley-Mein G. (1986) Primary thrombocythaemia treated with busulphan. Br. J. Haematol., 62, 229–37.
   PubMed Web of Science ®Google Scholar
• Mazzucconi M. G., Francesconi M., Chistolini A., Falcione E., Ferrari A., Tirindelli M. C., Mandelli F. (1986) Pipobroman therapy of essential thrombocythemia. Scandinavian Journal of Haematol, 37, 306–9.
   PubMedGoogle Scholar
• Brusamolino E., Canevari A., Salvaneschi L., Merante S., Bernasconi C. (1984) Efficacy trial of Pipobroman in essential thrombocythemia: a study of 24 patients. Cancer Treament Reports, 68, 1339–42.
   PubMedGoogle Scholar
• Lengfelder E., Griesshammer M., Hehlmann R. (1996) Interferon-alpha in the treatment of essential thrombocythemia. Leukemia and Lymphoma, 22 (suppl.1), 135–142.
   PubMed Web of Science ®Google Scholar
• Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am. J. Med., 92, 69–76.
   PubMed Web of Science ®Google Scholar